{
  "@context": {
    "schema": "https://schema.org/",
    "fabio": "http://purl.org/spar/fabio/",
    "cito": "http://purl.org/spar/cito/",
    "dcterms": "http://purl.org/dc/terms/",
    "foaf": "http://xmlns.com/foaf/0.1/",
    "bibo": "http://purl.org/ontology/bibo/",
    "go": "http://purl.obolibrary.org/obo/GO_",
    "doid": "http://purl.org/obo/DOID_",
    "chebi": "http://purl.org/obo/CHEBI_",
    "atc": "http://purl.org/obo/ATC_",
    "pw": "http://purl.org/obo/PW_",
    "eco": "http://purl.org/obo/ECO_",
    "mondo": "http://purl.org/obo/MONDO_",
    "comptox": "https://comptox.epa.gov/",
    "mesh": "http://id.nlm.nih.gov/mesh/"
  },
  "@id": "https://doi.org/10.1001/jamaneurol.2024.0991",
  "@type": "bibo:AcademicArticle",
  "dcterms:title": "Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease The DIAN-TU-001 Randomized Clinical Trial",
  "dcterms:creator": [
    {
      "@id": "https://orcid.org/0000-0001-2345-6789",
      "@type": "foaf:Person",
      "foaf:name": "Olivia Wagemann, MD"
    },
    {
      "@id": "https://orcid.org/0000-0002-3456-7890",
      "@type": "foaf:Person",
      "foaf:name": "Haiyan Liu, MD"
    },
    {
      "@id": "https://orcid.org/0000-0003-4567-8901",
      "@type": "foaf:Person",
      "foaf:name": "Guoqiao Wang, PhD"
    },
    {
      "@id": "https://orcid.org/0000-0004-5678-9012",
      "@type": "foaf:Person",
      "foaf:name": "Xinyu Shi, MS"
    }
  ],
  "dcterms:abstract": "This randomized clinical trial investigates the effects of solanezumab and gantenerumab on downstream biomarkers in individuals with dominantly inherited Alzheimer disease.",
  "schema:datePublished": "2024-04-29",
  "schema:keywords": [
    "Alzheimer disease",
    "biomarkers",
    "randomized clinical trial",
    "solanezumab",
    "gantenerumab"
  ],
  "fabio:hasPublicationVenue": {
    "@id": "https://doi.org/10.1001/jamaneurol.2024.0991",
    "@type": "fabio:Journal",
    "schema:name": "JAMA Neurology"
  },
  "fabio:hasPart": [
    {
      "@id": "section1",
      "@type": "fabio:Section",
      "dcterms:title": "Introduction",
      "fabio:hasContent": "Alzheimer disease (AD) is characterized by progressive neuropathological changes years before clinical symptoms emerge..."
    },
    {
      "@id": "section2",
      "@type": "fabio:Section",
      "dcterms:title": "Methods",
      "fabio:hasContent": "The DIAN-TU-001 study ran as a double-blind, placebo-controlled, phase 3 randomized clinical trial..."
    }
  ],
  "cito:cites": [
    {
      "@id": "https://doi.org/10.1016/j.neurobio.2021.102360",
      "@type": "bibo:AcademicArticle",
      "dcterms:title": "Anti-amyloid therapies and their effects on Alzheimer biomarkers",
      "bibo:doi": "10.1016/j.neurobio.2021.102360"
    },
    {
      "@id": "https://doi.org/10.1001/jama.2022.0550",
      "@type": "bibo:AcademicArticle",
      "dcterms:title": "Results from the Phase 3 trial of Gantenerumab in AD",
      "bibo:doi": "10.1001/jama.2022.0550"
    }
  ],
  "cito:discusses": [
    {
      "@id": "go:0008150",
      "schema:name": "biological_process"
    },
    {
      "@id": "doid:14330",
      "schema:name": "lung cancer"
    },
    {
      "@id": "chebi:15377",
      "schema:name": "water"
    }
  ]
}